Symbols

FNA(Delisted)

Paragon 28·NYSE

--(--)

Signals Analysis

Bullish signal 2

Bearish signal 0

Revenue Beats Expectation

EPS Beats Expectation

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About FNA

Paragon 28, Inc.

A leading medical device company exclusively focused on the foot and ankle orthopedic market

Industry

Established Date

Listing Date

10/15/2021

Exchange

New York Stock Exchange

Full-time Employees

525

Fiscal Year Ends

12-31

Website

www.paragon28.com

Security Type

Common stock

Office address

14445 Grasslands Drive, Englewood, CO 80112

Business

Introduction

Paragon 28, Inc., is incorporated in Delaware. The company is a leading medical device company focused on the foot and ankle orthopedics market, dedicated to improving the lives of patients. The company's innovative orthopedic solutions, surgical methods and instruments cover a wide range of foot and ankle diseases, including fracture fixation, hallux valgus (bunion), hammer toe, ankle, progressive collapsed foot deformity (PCFD or flat foot), charcot foot and orthopedic biological agents. To treat these painful, debilitating and even life-threatening diseases, they offer a comprehensive portfolio of solutions, including surgical implants and disposables, as well as surgical instruments. The company's extensive suite of surgical solutions includes 72 product systems, including approximately 8,700 SKUs, to help meet the specific needs of each patient and surgery. The company designs each product with patients and surgeons in mind, with the goal of improving outcomes, reducing disease recurrence and complication rates, and making procedures simpler, consistent and repeatable. The Company believes that their passion, expertise and focus on the ankle market enables them to better understand the needs of patients and physicians, which enables them to create innovative and enhanced solutions that disrupt and transform the ankle market.

Company Financials

EPS

FNA has released its 2024 Q3 earnings. EPS was reported at -0.15, versus the expected -0.16, beating expectations. The chart below visualizes how FNA has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

FNA has released its 2024 Q4 earnings report, with revenue of 71.75M, reflecting a YoY change of 18.47%, and net profit of -11.12M, showing a YoY change of 50.19%. The Sankey diagram below clearly presents FNA's revenue sources and cost distribution.